The company said revenues increased 8% in Q3 2024 and 7% year-to-date, driven by the Growth Portfolio and Eliquis, which were partially offset by Sprycel due to generic erosion.

1. 01

   The company said revenues increased 8% in Q3 2024 and 7% year-to-date, driven by the Growth Portfolio and Eliquis, which were partially offset by Sprycel due to generic erosion.

2. 02

   The company said its year-to-date GAAP EPS decreased by $7.44, citing one-time Acquired IPRD charges ($6.28) from the Karuna asset acquisition and the SystImmune collaboration as the main factor. After adjusting for specified items, the company said its non-GAAP EPS decreased by $6.33.

3. 03

   The company said it completed the acquisitions of Karuna, RayzeBio and Mirati in 2024, and it said it received FDA approval for Cobenfy, a treatment for schizophrenia in adults, in September 2024.

4. 04

   The company said that for the nine months ended September 30, 2024, cash from operating activities increased by $1.1 billion from 2023, and cash used in investing activities increased by $20.2 billion. It said net debt issuance of $10.5 billion in 2024 was primarily used to fund acquisitions.

Key figures

Quarter ended September 30, 2024

Revenue

$11.9B

Net income

$1.2B

EPS

$0.60

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.